Brief: Codexis And Nestlé Health Science Announce Interim Results From Phase 1 Clinical Trial Of Cdx-7108 For Exocrine Pancreatic Insufficiency

Codexis

24/02/2023 24:16

Feb 23 (Reuters) - Codexis Inc  CDXS.O :
    * CODEXIS AND NESTLÉ HEALTH SCIENCE ANNOUNCE INTERIM RESULTS
FROM
PHASE 1 CLINICAL TRIAL OF CDX-7108 FOR EXOCRINE PANCREATIC
INSUFFICIENCY
    * CODEXIS INC - CO AND NESTLÉ HEALTH SCIENCE EXPECT TO FILE
AN
INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR PHASE 2 STUDY BY
END OF 2023
    * CODEXIS INC - PHASE 2 STUDY IS EXPECTED TO BE CONDUCTED
OVER
APPROXIMATELY 12 MONTHS, WITH TOPLINE DATA EXPECTED IN 2025
    * CODEXIS INC - NO SAFETY ISSUES WERE NOTED IN TRIAL

Source text for Eikon:  ID:nGNXbqJfX3 
Further company coverage:  CDXS.O 
 ((Reuters.Briefs@thomsonreuters.com;))